Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 8/20 | 0.60 |
| ▸ | PPARA | Q07869 | 3/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 3/20 | 0.54 |
| ▸ | TACR1 | P25103 | 2/20 | 0.54 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | TDO2 | P48775 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2912586 | 1.00 | CASP1 (0.60) | CASP1PPARAPPARGCTSKTACR1 | |
| SCHEMBL2912589 | 1.00 | CASP1 (0.60) | CASP1PPARAPPARGCTSKTACR1 | |
| SCHEMBL7975561 | 0.92 | CASP1 (0.55) | CASP1PPARAPPARGCTSKCTSL | |
| SCHEMBL3012469 | 0.91 | CASP1 (0.56) | CASP1PPARAPPARGCTSKTACR1 | |
| SCHEMBL755795 | 0.91 | MMP9 (0.52) | CASP1PPARAPPARGCTSKCTSL | |
| SCHEMBL8116799 | 0.91 | CASP1 (0.56) | CASP1PPARAPPARGCTSKTACR1 | |
| SCHEMBL3012475 | 0.91 | CASP1 (0.56) | CASP1PPARAPPARGCTSKTACR1 | |
| SCHEMBL9312398 | 0.91 | CASP1 (0.60) | CASP1CTSKTACR1CTRB1CTSL | |
| SCHEMBL8765627 | 0.91 | CASP1 (0.60) | CASP1CTSKTACR1CTRB1CTSL | |
| SCHEMBL376886 | 0.89 | CASP1 (0.67) | CASP1PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116075499-A | Novel dephosphorylated galectin derivatives with prodrug properties | 指南针探路者有限公司 | 2023-05-05 | — | — | CN | claimed |
| EP-0284084-B1 | INTENSELY SWEET L-ASPARTYL-3-(BICYCLOALKYL)-L-ALANINE ALKYL ESTERS | THE COCA-COLA COMPANY (US) | 1991-06-26 | — | — | EP | claimed |
| EP-0284084-A2 | Intensely sweet L-aspartyl-3-(Bicycloalkyl)-L-alanine alkyl esters | THE COCA-COLA COMPANY (US) | 1988-09-28 | — | — | EP | claimed |
| JP-61291596-A | — | — | None | — | — | JP | disclosed |
| JP-61291597-A | — | — | None | — | — | JP | disclosed |
| JP-59163354-A | — | — | None | — | — | JP | disclosed |
| JP-62067098-A | — | — | None | — | — | JP | disclosed |
| US-20260021190-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4615487-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | Merck Sharp & Dohme LLC (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| WO-2024102633-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC (US) | 2024-05-16 | — | — | WO | disclosed |
| EP-0186173-A2 | L-Aminodicarboxylic-(0-cycloalkyl)-L-aminocarboxylate alkyl esters, an edible composition containing same as sweeteners and a method for sweetening an edible composition | GENERAL FOODS CORPORATION (US) | 1986-07-02 | — | — | EP | disclosed |
| JP-S59163354-A | TRIPEPTIDE DERIVATIVE AND SWEETENER CONTAINING THE SAME | AJINOMOTO CO INC | 1984-09-14 | — | — | JP | disclosed |
| US-4338346-A | Non-nutritive sweetener | THE PROCTER & GAMBLE COMPANY (US) | 1982-07-06 | — | — | US | disclosed |
| EP-0013044-A1 | L-aspartyl amide derivatives and their use as sweetening agents | THE PROCTER & GAMBLE COMPANY (US) | 1980-07-09 | — | — | EP | disclosed |
| US-4175084-A | AND AN N-ACYL ASPARTIC ACID CARRIER, FOR PSYCHOLOGICAL DISORDERS, LEARNING ENHANCEMENT AND SLEEP INDUCTION | SENTRALINSTITUTT FOR INDUSTRIELL FORSKNING (NO) | 1979-11-20 | — | — | US | disclosed |
| US-4025551-A | 3-Amino-N-substituted succinamic acids | G. D. SEARLE & CO. (US) | 1977-05-24 | — | — | US | disclosed |
| US-4011260-A | 3-AMINO-N-SUBSTITUTED SUCCINAMIC ACIDS AND INTERMEDIATES THERETO | G. D. SEARLE & CO. (US) | 1977-03-08 | — | — | US | disclosed |
| US-3984417-A | Method of producing active amino acid esters | AJINOMOTO CO., INC. (JA) | 1976-10-05 | — | — | US | disclosed |
| US-3959245-A | SWEETENERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021190-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | INSR, GPR119, GLP1R | CASP1 3852/4885PPARA 1213/4885PPARG 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.